1However, the stimuli to AVP is likely different between cycling and running.
2Results: Twenty-two patients were found to carry a pathogenic AVP-NPII gene mutation.
3One AVP patient developed acute coronary syndrome with dose-dependent ECG changes.
4No differences were found for non-social working memory or for AVP vs placebo.
5We assessed the results of vascular embolization obtained using the AVP.
6The magnitude of the AVP-induced vasoconstriction was significantly reduced by calphostin-C.
7The modest decrease in PV was not the primary non-osmotic stimulus to AVP.
8The contents of SS and AVP in hippocampus tissue were measured by radioimmunoassay.
9Conclusions: Peripheral embolization with the AVP 4 was successful in the majority of patients.
10At the maximum effect, pinacidil completely relaxed vasoconstriction in the continuing exposure to AVP.
11These results suggest that periventricular dopaminergic mechanisms may act to inhibit hemorrhage-induced AVP secretion.
12The copeptin assay may be a useful alternative to direct measurement of AVP concentration.
13This study evaluated the AVP 4 in peripheral vascular embolization.
14Measurement of AVP levels has limitations due to its short half-life and cumbersome detection method.
15In ICU patients, AVP decreased to moderately elevated levels within 24 h after ED admission.
16It has been proposed that this is because AVP facilitates baroreflex control of the circulation.